A New Golden Age: How Europe, Spain in Particular-Is Re-Shaping Global Pharma
- Miguel Virgen, PhD Student in Business
- May 29, 2025
- 5 min read
The post-pandemic rebound has been kinder to European drug makers than many analysts dared hope. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), continental production hit an estimated €390 billion in 2023, with direct R&D spending topping €50 billion and head-count edging toward 900,000 high-skill jobs. Those figures matter not only for balance sheets; they signal that Europe has moved from defensive cost-cutting to an offensive growth stance, one driven by breakthrough modalities—cell and gene therapies, mRNA vaccines, targeted radiopharmaceuticals—and by regulatory tailwinds such as the new Health Technology Assessment Regulation that promises faster, more predictable market access.(ProPharma Group)
Want to read more?
Subscribe to doctorsinbusinessjournal.com to keep reading this exclusive post.
